Dexcom executive management
EVP, Regulatory Strategy, Clinical Affairs and Strategic Partnership Development
Board of directors
Steven R. Altman
Steven R. Altman joined the Dexcom Board of Directors in 2013. Up until his retirement from Qualcomm Incorporated in January 2014, Mr. Altman served as vice chairman of Qualcomm Incorporated and as a member of Qualcomm’s executive committee. In that role, Mr. Altman provided direction and guidance on key initiatives across all areas of the business, as well as on overall vision and strategy.
Mr. Altman joined Qualcomm in 1989 and was the chief architect of Qualcomm’s strategy for licensing its broad intellectual property portfolio for wireless communications, which has accelerated the growth of CDMA technology. In that role, he was responsible for structuring and negotiating Qualcomm’s license agreements, joint ventures and strategic relationships. Under Mr. Altman’s leadership, Qualcomm entered into domestic and international licensing agreements with the world's largest telecommunications and electronics companies.
Mr. Altman began his career with the San Diego law firm of Gray, Cary, Ames & Frye (which later become DLA Piper), where he specialized in intellectual property, mergers and acquisitions, securities, and general corporate matters. He joined Qualcomm in 1989 as corporate counsel with responsibility for licensing and contracts, quickly moving up through the management ranks and becoming vice president and general counsel in 1992. He became general manager of QTL when that organization was formed in 1995; and senior vice president in 1996. In 1998, Mr. Altman was named executive vice president; and president of QTL in 2000. From 2005 to 2011, Mr. Altman served as the president of Qualcomm where his leadership and contributions helped enable Qualcomm’s successful growth, evolution and expansion.
Mr. Altman graduated from Northern Arizona University in 1983 with a bachelor’s degree in political science and administration; he received his Juris Doctor from the University of San Diego School of Law in 1986. Mr. Altman served as a board member of Ubiquiti Networks, Inc. from October 2013 to December 2015. He is also a member of the University of California at San Diego (UCSD) Health Board of Advisors, Mr. Altman also serves as a board member for privately-held companies ViaCyte Inc. and Brain Corporation. As a former board member of the Juvenile Diabetes Research Foundation (JDRF), he remains an active supporter of the JDRF and numerous other charitable causes.
Nicholas (Nick) Augustinos has served on our Board since November 2009. Nick is the President & CEO of Aver, Inc. a company specializing in bundled payment and analytics solutions. Besides his role as President & CEO Nick serves on the Board of Directors of Aver, Inc. Prior to Aver, Inc., Nick was the Senior Vice President Health Information Services and Strategy at Cardinal Health. In January 2015, he was appointed to the Board of Directors of the California Health Care Foundation (CHCF). CHCF has as its mission to improve care for all Californians through innovations that improve quality, increase efficiency, and lower the cost of care. Prior to CHCF Nick served on the Board of Directors of the SCAN Foundation (June 2011 - December 2014), an organization dedicated to advancing the development of a sustainable continuum of quality care for seniors. Nick served on the Board of Directors of Audax Health, now Rally (March 2012 - February 2014), specializing in consumer engagement solutions. Rally is currently part of Optum, a UnitedHealth Group company. Nick brings 30 years of broad managerial, consulting and business development experience in the private and public sector. He has worked with a diverse range of leading healthcare delivery systems, healthcare insurers and government organizations globally.
Prior to Cardinal Health, Nick was the Senior Director for Global Healthcare Operations at Cisco Systems, leading the go to market strategy for healthcare focusing on public sector bringing business and technical expertise along with thought leadership towards in the areas of connected health, wellness and care delivery. Nick started his career at Cisco as the Senior Director for Global Healthcare Solutions of the Internet Business Solutions Group – the strategic consulting business unit of Cisco – he led among other initiatives the Cisco HealthPresence™ development, Cisco’s core care-at-a-distance platform.
Prior to Cisco, Nick was Partner and Senior Strategic Consulting Expert, Global Health Services, for CSC. Prior to joining CSC, he was Vice President, Care Data Exchange business unit for CareScience, leading product development and services in the clinical document sharing space. Nick was also Vice President for Healtheon/ WebMD, responsible for marketing and sales for the company’s products and services. Prior to that, he was with Deloitte Consulting and was instrumental in establishing the healthcare practice for Deloitte’s San Francisco office, managing numerous projects for payers, providers, and integrated delivery networks. He started his career in healthcare as Vice President, Administration, of CliniShare.
Richard Collins has served on our Board since March 2017.
Mr. Collins has been a self-employed consultant since October 2013. From March 2011 to October 2013 Mr. Collins was the Chief Executive Officer for UnitedHealthcare’s Northeast Region and was at different times the President, Director or Chairman of numerous UnitedHealthcare subsidiaries including Oxford Health Plans, Mid Atlantic Medical Services and UHC Insurance Company of New York. From July 2005 through December 2012 Mr. Collins served as President – Individual Line of Business for UnitedHealthcare and as the Chairman and Chief Executive Officer of Golden Rule Financial Corporation. Prior to 2011, Mr. Collins also held leadership positions in pricing, underwriting and healthcare economics with UnitedHealthcare. During his tenure there, Mr. Collins saw UnitedHealthcare grow from a mid-cap health insurer into one the largest public corporations in America.
Mr. Collins has previously served on the Boards of Fairbanks Hospital in Indianapolis, Indiana, The Indiana Chapter of The Nature Conservancy, UnitedHealthcare Children’s Foundation, and the Council for Affordable Health Insurance.
Mr. Collins brings significant experience in healthcare insurance and administration to our Board.
Karen Dahut joined the Dexcom Board of Directors in 2020. Ms. Dahut currently holds the position of Executive Vice President and Senior Partner at Booz Allen Hamilton, a leading global consulting firm to business, government, and military clients. In her role today, Ms. Dahut serves as Group Leader of the firm’s Global Commercial and Global Defense Business, where she is responsible for directing the strategy and delivery of the firm’s strategic, technology, cyber, and analytics solutions. Prior to assuming this role in 2017, Ms. Dahut held several leadership positions throughout the organization, including Chief Innovation Officer; Leader, Analytics and Data Science Business; and Leader, Economic and Business Analytics Capability. Before joining Booze Allen, Ms. Dahut served as comptroller for the Navy’s premier biomedical research institute and as a United States Naval Officer.
Ms. Dahut also actively serves on the Board of Directors for the National Air and Space Museum and Northern Virginia Technology Council. She previously served on the Board of Directors of Tech Data Corporation, an end-to-end technology distributor and Fortune 100 company, prior to its acquisition by Apollo Global Management in 2020.
She holds an MS from the University of Southern California’s Viterbi School of Engineering and a bachelor’s degree in Finance from Mount Saint Mary’s University.
Mark Foletta has considerable audit and financial experience in the biotechnology and pharmaceutical sectors. Mr. Foletta previously served as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., a public pharmaceutical company, from March 2006 through Amylin’s acquisition by Bristol Myers-Squibb Company in August 2012, and as Vice President, Finance and Chief Financial Officer of Amylin from 2000 to 2006. Prior to joining Amylin in 2000, Mr. Foletta held a number of management positions with Intermark, Inc. and Triton Group Ltd. from 1986 to 2000 and served as an Audit Manager with Ernst & Young. Mr. Foletta served as a director of Anadys Pharmaceuticals, Inc., a publicly-held biopharmaceutical company now owned by F. Hoffmann-La Roche Inc., from September 2005 through November 2011. He is currently a member of the Board of Directors and Audit Committee of AMN Healthcare Services, Inc., a publicly traded healthcare workforce solutions provider, and Regulus Therapeutics, Inc., a publicly traded biopharmaceutical company. He is also on the Board of Directors of Viacyte, Inc., a private biotechnology company. Mr. Foletta received a B.A. in Business Economics from the University of California, Santa Barbara and is a member of the Corporate Directors Forum.
Bridgette Heller has served on the Board since September 2019. Ms. Heller brings to our Board considerable experience in business, specifically as it relates to technology and manufacturing, and she is a strong addition to the Board as Dexcom continues to expand and scale its operations.
Ms. Heller is a co-founder and the CEO of a small nonprofit, the Shirley Proctor Puller Foundation, committed to generating better educational outcomes for underserved children in St. Petersburg, Florida. Previously, Ms. Heller served as the EVP and President of Nutricia, the Specialized Nutrition Division of Danone from July 2016 to August 2019. From 2010 to 2015, she served as Executive Vice President of Merck & Co., Inc. and President of Merck Consumer Care. Prior to joining Merck, Ms. Heller was President of Johnson & Johnson’s Global Baby Business Unit from 2007 to 2010 and President of its Global Baby, Kids, and Wound Care business from 2005 to 2007. She also worked for Kraft Foods from 1985 to 2002, ultimately serving as Executive Vice President and General Manager for the North American Coffee Portfolio.
Ms. Heller also serves on the Boards of Novartis and Tech Data Corporation.
She holds an MBA from Northwestern University’s Kellogg Graduate School of Management and is a member of the school’s Advisory Board. Ms. Heller received her bachelor’s degree in Economics and Computer Studies from Northwestern University.
Barbara E. Kahn
Barbara Kahn is the Patty and Jay J. Baker Professor of Marketing at The Wharton School at the University of Pennsylvania. Prior to rejoining Wharton, Ms. Kahn served for three and a half years as the Dean and Schein Family Chair Professor of Marketing at the School of Business Administration, University of Miami. While Dean at the University of Miami, she launched new global initiatives and academic programs, attracted top faculty from some the of the world’s leading business schools to enhance the caliber of the school’s research and teaching, and established new partnerships with the business community. Before becoming Dean at the University of Miami, Ms. Kahn spent 17 years at The Wharton School as the Dorothy Silberberg Professor of Marketing and served as Vice Dean and Director of the Wharton undergraduate program. Ms. Kahn was also a Senior Fellow of the Leonard Davis Institute and a faculty member of the Graduate Group in the Psychology Department.
Ms. Kahn is an internationally recognized scholar on variety seeking, brand loyalty, retail assortment issues and patient decision-making whose research provides marketing managers with better understanding of the consumer choice process. She has published more than 60 articles in leading academic journals. Ms. Kahn has been elected president of the Association of Consumer Research, president of the Journal of Consumer Research Policy Board and selected as a Marketing Science Institute Trustee. Ms. Kahn served as area editor at Marketing Science and associate editor at the Journal of Consumer Research, as well as serving on or having served on the editorial boards of the Journal of Marketing Research, Marketing Science, the Journal of Marketing, the Journal of Consumer Research, the Journal of Behavioral Decision Making and Marketing Letters. She has been elected a Fellow of the Association of Consumer Research and a Fellow of Society for Consumer Psychology.
Kyle Malady joined the Dexcom Board of Directors in 2020. Mr. Malady currently serves as executive vice president of global networks and technology & chief technology officer at Verizon Communications Inc. In this role, Mr. Malady leads the company’s network operations, IT functions, data center management, and customer facing new product realization.
Prior to assuming this role, Mr. Malady was head of the Core Engineering and Operations organization within the Global Network and Technology organization. He has also served as Verizon’s vice president of New Product Development, including an instrumental role in the development and commercialization of 4G LTE
In addition to his experience at Verizon, Mr. Malady manages Caelens Fund, a charity that raises money to provide free cardiac surgeries for children in developing countries. Mr. Malady holds an MBA in finance from the NYU Stern School of Business and Bachelor of Science in Mechanical Engineering from the University of Bridgeport.
Kevin Sayer is the Chairman of the Board of Directors, President and Chief Executive Officer of Dexcom
Kevin assumed the role of CEO in January 2015 and became Chairman of the Board in July 2018. Kevin has also served as our President since 2011. He held the role of Chief Operating Officer from January 2013 until January 2015. Kevin has served as a member of Dexcom’s Board of Directors beginning in November 2007, prior to his role as Chairman and CEO.
Prior to leading Dexcom, Kevin held various management positions in his prior roles. He served as Chief Financial Officer of Biosensors International Group, Ltd., Executive Vice President and Chief Financial Officer of Specialty Laboratories, Inc., Chief Financial Officer of MiniMed, Inc., and Vice President and General Manager of Medtronic MiniMed after the acquisition of MiniMed by Medtronic.
Kevin is a Certified Public Accountant (inactive) and received a Bachelor’s degree and a Master's degree in Accounting and Information Systems from Brigham Young University.
Jay Skyler, M.D.
Dr. Jay S. Skyler is a Professor of Medicine, Pediatrics, & Psychology at the University of Miami, Miami, Florida, in the Division of Endocrinology, Diabetes, & Metabolism in the Department of Medicine, of which he was the Director from 2000 to 2004; and Deputy Director for Clinical Research and Academic Programs in the Diabetes Research Institute. For 22 years, Dr. Skyler also served as Study Chairman for the National Institute of Diabetes & Digestive & Kidney Diseases Type 1 Diabetes clinical trials network, conducting clinical trials to prevent type 1 diabetes or interdict the type 1 diabetes disease process. His research interests are in clinical aspects of diabetes, particularly improving the care of type 1 diabetes through meticulous glycemic control, psychosocial and behavioral support, and immune intervention. He is widely acclaimed for developing "algorithms" for patient adjustment of insulin doses.
Dr. Skyler is a past President of the American Diabetes Association, the International Diabetes Immunotherapy Group, and the Southern Society for Clinical Investigation, and was a Vice President of the International Diabetes Federation. He served as a member of the Endocrinology, Diabetes, and Metabolism Subspecialty Examining Board of the American Board of Internal Medicine, as Chairman of the Council of Subspecialty Societies of the American College of Physicians (ACP) and a member of the ACP Board of Regents. He was founding Editor-in-Chief of Diabetes Care, and currently is Senior Editor of Diabetes Technology & Therapeutics.
He has a bachelor of science degree from Pennsylvania State University and a doctor of medicine degree from Jefferson Medical College. He served as an intern, resident, and fellow, and was on the faculty of Duke University.
Eric J. Topol, M.D.
Eric J. Topol, M.D. is the Director of the Scripps Translational Science Institute, a National Institutes of Health funded program of the Clinical and Translational Science Award (CTSA) Consortium. In 2009, he was named the Gary and Mary West Endowed Chair of Innovative Medicine. He is Executive Vice President and Professor of Molecular Medicine at The Scripps Research Institute and a Senior Consultant cardiologist practitioner at Scripps Clinic.
Prior to coming to Scripps, he served on the faculty of Case Western as a professor in genetics, chaired the Department of Cardiovascular Medicine at Cleveland Clinic for 15 years and raised its status to rank #1 by US News and World Report for 11 consecutive years, and founded the Cleveland Clinic Lerner College of Medicine. His work in the genomics of heart attack has led to discovery of key genes (MEF2A deletion, THSB-4 variant) which led to recognition by the American Heart Association top 10 research advances in 2002 and 2004. As a leader in clinical trials of novel therapeutics, he administered recombinant t-PA to the first patient in 1984, pioneered and led the clinical development of clopidogrel (Plavix), bivalirudin (Angiomax), and abciximab (ReoPro). He has over 1,100 original peer reviewed publications, and has edited over 30 books, including the Textbook of Interventional Cardiology (5th ed), and the Textbook of Cardiovascular Medicine (3rd ed). Dr. Topol has been elected to the Institute of Medicine of the National Academy of Sciences, the American Association of Physicians and recognized by the Institute of Scientific Information (ISI) to be in the top 10 cited biomedical researchers in medicine in the past decade.
Dr. Topol has also been a medical innovator in digital medicine, having authored two best seller books on the topic – The Creative Destruction of Medicine (2012) and The Patient Will See You Now (2015).